Showing posts with label CYP3A4. Show all posts
Showing posts with label CYP3A4. Show all posts
Sunday, April 24, 2011
abstract: Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer (inhibitors)
PURPOSE:
Patupilone is a novel microtubule-targeting cytotoxic agent with potential interaction with CYP3A4/CYP2C19 enzymes. Midazolam and omeprazole are primarily metabolized by CYP3A4 and CYP2C19, respectively. We evaluated the inhibitory effects of patupilone on the CYP3A4/CYP2C19 pathways.
METHODS:
This study had 2 parts: in an initial core phase, patients were randomly assigned to receive midazolam 4 mg or omeprazole 40 mg PO (days 1 and 29) and patupilone 10 mg/m(2) IV (days 8 and 29). Patients without progression continued patupilone every 3 weeks until disease progression or unacceptable toxicity (extension phase).
add your opinions
CYP2C19
,
CYP3A4
,
inhibitors
,
Patupilone
Subscribe to:
Posts
(
Atom
)